BRCA2 and cancer: Such a mechanism could be the basis for the use of PARP inhibitors to kill selectively cancer cells as in the case of synthetic lethality observed for BRCA1 and BRCA2 deficiency (28,29) but also for deficiencies in other HR relevant factors such as rad51 (30).